Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Press Release Tenpoint Therapeutics, Limited ("Tenpoint") and Visus Therapeutics, Inc., ("Visus") announce today the completion of their merger to create an entirely new chapter in ophthalmic ...

The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...

2024 was another year of the humanoids, with six of our top 10 stories being about or mentioning humanoid robots.

Other notable investors: Amgen, Arch Venture Partners, Alexandria Venture Investments, Altitude Life Science Ventures, Catalio Capital Management, Citadel, F-Prime Capital, Logos Capital ...

Founded by Wei Wang in 2013, Canoe has now raised a total of $25.0M in total equity funding and is backed by The Carlyle Group, F-Prime Capital, Hamilton Lane, Eight Roads Ventures, and Nasdaq ...